China's Zhaoke Ophthalmology H1 revenue rises
China's Zhaoke Ophthalmology H1 revenue rises
Overview
China ophthalmic drug maker's interim revenue rose yr/yr to RMB 18.8 mln
Non-HKFRS adjusted loss for the period widened slightly to RMB 116.1 mln
Company advanced regulatory filings for key drugs and expanded global partnerships
Outlook
Company expects flagship products to progress through regulatory reviews in China and Australia
YUVEZZI has received regulatory approval in Hainan and Macau; commercialization sought in Greater Bay Area
Company expanding international footprint with partnerships in Singapore and Vietnam
Result Drivers
REGULATORY PROGRESS - Co advanced regulatory filings for flagship drug candidates in China and internationally
NEW DRUG APPROVALS - Co received regulatory approvals for presbyopia drug YUVEZZI in Hainan and Macau
INTERNATIONAL EXPANSION - Co expanded global partnerships and commercialization efforts in Singapore and Vietnam
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| RMB 18.83 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Reuters Recommended Reads
Aug 28 - China's Chaoju Eye Care H1 net profit falls on lower insurance pricing
Aug 26 - China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales
Aug 27 - China's CStone Pharmaceuticals H1 revenue soars on drug sales
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital